SB may regulate TRP-induced bone metabolism abnormalities in LNCaP cells through the IL-17 signaling pathway as well as five DEPs: p-ERK2, RELA, HSP90B1, GNAI1and GNAI3.

5 days ago

Journal

IL17A (Interleukin 17A) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • RELA (RELA Proto-Oncogene)

triptorelin

11d

NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov)

P2, N=32, Recruiting, Rana McKay, MD | Trial primary completion date: Dec 2025 --> Mar 2026

11 days ago

Trial primary completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L2 (RAD54 Like 2)

Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension

12d

MESURE: MEdical Versus SUrgical Treatments of Rectal Endometriosis (clinicaltrials.gov)

P3, N=78, Completed, University Hospital, Rouen | Unknown status --> Completed

12 days ago

Trial completion

triptorelin • cyproterone acetate

18d

PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (clinicaltrials.gov)

P2, N=231, Completed, ETOP IBCSG Partners Foundation | Recruiting --> Completed | Trial completion date: Jun 2026 --> Sep 2025 | Trial primary completion date: Jun 2026 --> Sep 2025

18 days ago

Trial completion • Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)

ER positive • HER-2 negative

anastrozole • triptorelin • giredestrant (RG6171)

20d

EPIBREAST: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. (clinicaltrials.gov)

P2, N=51, Not yet recruiting, UNICANCER

20 days ago

New P2 trial • Tumor mutational burden

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)

ER positive • HER-2 negative • HER-2 mutation • HER-2 negative + ER positive

fulvestrant • triptorelin • prifetrastat (PF-07248144)

20d

APEX: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P2, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Jan 2026 --> Jan 2027

20 days ago

Trial primary completion date

Xtandi (enzalutamide) • Eligard (leuprolide acetate) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix)

28d

FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov)

P2/3, N=260, Not yet recruiting, Fudan University

28 days ago

New P2/3 trial • Tumor mutational burden

PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)

ER positive • MSI-H/dMMR

Tyvyt (sintilimab) • letrozole • triptorelin • megestrol

HypoFocal SRT: Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy (clinicaltrials.gov)

P=N/A, N=36, Active, not recruiting, Insel Gruppe AG, University Hospital Bern | Recruiting --> Active, not recruiting | Trial completion date: Aug 2027 --> Nov 2027 | Trial primary completion date: Sep 2025 --> Nov 2027

1 month ago

Enrollment closed • Trial completion date • Trial primary completion date

bicalutamide • triptorelin

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)

P2, N=532, Recruiting, Mayo Clinic | N=220 --> 532

1 month ago

Enrollment change

Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension

2ms

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov)

P2, N=112, Not yet recruiting, Fudan University

2 months ago

New P2 trial

docetaxel • abiraterone acetate • triptorelin • goserelin acetate • Firmagon (degarelix)

2ms

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (clinicaltrials.gov)

P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Sep 2026

2 months ago

Trial completion date

abiraterone acetate • triptorelin • goserelin acetate

2ms

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)

P2, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Nov 2028 | Trial primary completion date: Jan 2027 --> Nov 2028

2 months ago

Enrollment closed • Trial completion date • Trial primary completion date

docetaxel • Xtandi (enzalutamide) • Nubeqa (darolutamide) • apalutamide • triptorelin • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension